A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

Exclusion Criteria

• •History of any clinically significant disease that put the participant at risk of participation.
• •History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• •Any clinically significant illness, medical/surgical procedure, history of narrow angle glaucoma not adequately treated, or bladder neck obstruction/urinary retention.
• •Unresectable cancer that has not been in complete remission for at least 5 years.
• •Any clinically significant abnormal findings in physical examination, clinical chemistry, hematology, urinalysis results, or vital signs at Screening.
• •Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at Screening.
• •Any positive result on Screening for serum hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) antibodies.
• •History of any respiratory disorders such as asthma, COPD, or idiopathic pulmonary fibrosis.
• •History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity.
• •Known or suspected history of alcohol or drug abuse as judged by the Investigator.
• •Current smokers or those who have smoked or used nicotine products (including e cigarettes).
• •Excessive intake of caffeine-containing drinks or food.